513 related articles for article (PubMed ID: 27401249)
21. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
Abiko K; Matsumura N; Hamanishi J; Horikawa N; Murakami R; Yamaguchi K; Yoshioka Y; Baba T; Konishi I; Mandai M
Br J Cancer; 2015 Apr; 112(9):1501-9. PubMed ID: 25867264
[TBL] [Abstract][Full Text] [Related]
22. Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer.
Donnem T; Al-Shibli K; Andersen S; Al-Saad S; Busund LT; Bremnes RM
Cancer; 2010 Sep; 116(18):4318-25. PubMed ID: 20549821
[TBL] [Abstract][Full Text] [Related]
23. Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium.
Guan J; Darb-Esfahani S; Richter R; Taube ET; Ruscito I; Mahner S; Woelber L; Prieske K; Concin N; Vergote I; Van Nieuwenhuysen E; Achimas-Cadariu P; Glajzer J; Woopen H; Stanske M; Kulbe H; Denkert C; Sehouli J; Braicu EI
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1063-1073. PubMed ID: 30810838
[TBL] [Abstract][Full Text] [Related]
24. Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia.
Gebhardt M; Mentlein R; Schaudig U; Pufe T; Recker K; Nölle B; Al-Samir K; Geerling G; Paulsen FP
Ophthalmology; 2005 Jun; 112(6):1023-30. PubMed ID: 15885787
[TBL] [Abstract][Full Text] [Related]
25. [Expressions of VEGF/VEGFRs and activation of STATs in ovarian carcinoma].
Chen BY; Ye DF; Xie X; Chen HZ; Lü WG
Zhonghua Zhong Liu Za Zhi; 2005 Jan; 27(1):33-7. PubMed ID: 15771796
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity.
Mao Y; Sarhan D; Steven A; Seliger B; Kiessling R; Lundqvist A
Clin Cancer Res; 2014 Aug; 20(15):4096-106. PubMed ID: 24907113
[TBL] [Abstract][Full Text] [Related]
27. Quantitative assessment and clinical relevance of VEGFRs-positive tumor cells in refractory brain tumors.
Tamura R; Sato M; Morimoto Y; Ohara K; Kosugi K; Oishi Y; Kuranari Y; Murase M; Yoshida K; Toda M
Exp Mol Pathol; 2020 Jun; 114():104408. PubMed ID: 32088190
[TBL] [Abstract][Full Text] [Related]
28. GDNF increases cell motility in human colon cancer through VEGF-VEGFR1 interaction.
Huang SM; Chen TS; Chiu CM; Chang LK; Liao KF; Tan HM; Yeh WL; Chang GR; Wang MY; Lu DY
Endocr Relat Cancer; 2014 Feb; 21(1):73-84. PubMed ID: 24165321
[TBL] [Abstract][Full Text] [Related]
29. [Analysis of VEGF-A/VEGFR1/VEGFR2 gene expression in patients with myelodysplastic syndrome].
Kalitin NN; Dudina GA; Semochkin SV; Karamysheva AF
Ter Arkh; 2017; 89(7):39-44. PubMed ID: 28766539
[TBL] [Abstract][Full Text] [Related]
30. Glucose-regulated protein 78 silencing down-regulates vascular endothelial growth factor/vascular endothelial growth factor receptor 2 pathway to suppress human colon cancer tumor growth.
Kuo LJ; Hung CS; Chen WY; Chang YJ; Wei PL
J Surg Res; 2013 Nov; 185(1):264-72. PubMed ID: 23759331
[TBL] [Abstract][Full Text] [Related]
31. Tumor-derived vascular endothelial growth factor (VEGF)-a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway.
Liu W; Xu J; Wang M; Wang Q; Bi Y; Han M
Int J Oncol; 2011 Nov; 39(5):1213-20. PubMed ID: 21785819
[TBL] [Abstract][Full Text] [Related]
32. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
Khan AN; Kolomeyevskaya N; Singel KL; Grimm MJ; Moysich KB; Daudi S; Grzankowski KS; Lele S; Ylagan L; Webster GA; Abrams SI; Odunsi K; Segal BH
Oncotarget; 2015 May; 6(13):11310-26. PubMed ID: 25888637
[TBL] [Abstract][Full Text] [Related]
33. Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α.
Najjar YG; Rayman P; Jia X; Pavicic PG; Rini BI; Tannenbaum C; Ko J; Haywood S; Cohen P; Hamilton T; Diaz-Montero CM; Finke J
Clin Cancer Res; 2017 May; 23(9):2346-2355. PubMed ID: 27799249
[No Abstract] [Full Text] [Related]
34. Vascular endothelial growth factor A (VEGF-A) is involved in guidance of VEGF receptor-positive cells to the anterior portion of early embryos.
Hiratsuka S; Kataoka Y; Nakao K; Nakamura K; Morikawa S; Tanaka S; Katsuki M; Maru Y; Shibuya M
Mol Cell Biol; 2005 Jan; 25(1):355-63. PubMed ID: 15601856
[TBL] [Abstract][Full Text] [Related]
35. [Prognostic value of tumor infiltration immune cells in pancreatic cancer].
Zhao KL; Liu J; Jiang WN; Hao JH
Zhonghua Wai Ke Za Zhi; 2018 Jun; 56(6):464-470. PubMed ID: 29886672
[No Abstract] [Full Text] [Related]
36. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer.
Kopparapu PK; Boorjian SA; Robinson BD; Downes M; Gudas LJ; Mongan NP; Persson JL
Anticancer Res; 2013 Jun; 33(6):2381-90. PubMed ID: 23749886
[TBL] [Abstract][Full Text] [Related]
37. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms.
Abu-Jawdeh GM; Faix JD; Niloff J; Tognazzi K; Manseau E; Dvorak HF; Brown LF
Lab Invest; 1996 Jun; 74(6):1105-15. PubMed ID: 8667614
[TBL] [Abstract][Full Text] [Related]
38. Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Nuti M; Taube ET; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
Br J Cancer; 2018 Aug; 119(3):330-338. PubMed ID: 29955134
[TBL] [Abstract][Full Text] [Related]
39. Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects.
Liang Y; Hyder SM
Endocrinology; 2005 Aug; 146(8):3632-41. PubMed ID: 15845615
[TBL] [Abstract][Full Text] [Related]
40. CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer.
Zhang H; Ye YL; Li MX; Ye SB; Huang WR; Cai TT; He J; Peng JY; Duan TH; Cui J; Zhang XS; Zhou FJ; Wang RF; Li J
Oncogene; 2017 Apr; 36(15):2095-2104. PubMed ID: 27721403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
